Drug Profile


Alternative Names: AZD 7371; NAD 299

Latest Information Update: 18 Nov 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antidepressants; Anxiolytics; Benzopyrans; Gastrokinetics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Gastrointestinal disorders; Irritable bowel syndrome; Major depressive disorder; Overactive bladder

Most Recent Events

  • 19 Aug 2002 Discontinued - Phase-II for Anxiety disorders in Sweden (unspecified route)
  • 19 Aug 2002 Discontinued - Phase-II for Depression in Sweden (unspecified route)
  • 04 May 2000 Phase-II clinical trials for Anxiety disorders in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top